

FILE 'REGISTRY' ENTERED AT 16:27:24 ON 22 FEB 2007

L17 STRUCTURE UPLOADED

L18 0 F L17

L19 0 S L17

L20 46 S L17 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:28:19 ON 22 FEB 2007

L21 19 S L20

L22 1 S L21 AND (SEPSIS OR SEPTIC)

L23 1 S L21 AND (SHOCK)

L24 2 S L20/THU

L25 2 S L21 AND (ANTIBACTERIAL)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 16:36:32 ON 22 FEB 2007
SEA SOPHOROLIPID AND SHOCK

1 FILE BIOSIS

2 FILE CAPLUS

SEA SOPHOROLIPID AND (SHOCK OR SEPSIS OR BACTEREMIA)

2 FILE BIOSIS

2 FILE CAPLUS

1 FILE DDFU

1 FILE DRUGU

2 FILE EMBASE

1 FILE IFIPAT

1 FILE MEDLINE

1 FILE PASCAL

3 FILE SCISEARCH

2 FILE TOXCENTER

5 FILE USPATFULL

1 FILE WPIDS

1 FILE WPIINDEX

L26 QUE SOPHOROLIPID AND (SHOCK OR SEPSIS OR BACTEREMIA)

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, USPATFULL' ENTERED AT 16:37:59
ON 22 FEB 2007

L27 13 S SOPHOROLIPID AND (SHOCK OR SEPSIS OR BACTEREMIA)

L28 10 DUP REM L27 (3 DUPLICATES REMOVED)

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	88.48	206.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.48	-20.28

FILE 'REGISTRY' ENTERED AT 16:27:24 ON 22 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2007 HIGHEST RN 922553-43-3
 DICTIONARY FILE UPDATES: 22 FEB 2007 HIGHEST RN 922553-43-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\10807961lipidgeneric2.str



```

chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 27 34 35
36 37 38 39 40 41 42 43
ring nodes :
21 22 23 24 25 26 28 29 30 31 32 33
chain bonds :
1-2 1-19 1-43 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
14-15 15-16 16-17 17-18 17-20 20-21 23-34 24-41 25-42 26-27 27-28 30-36
31-38 32-39
33-40 34-35 36-37
ring bonds :
21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-33 29-30 30-31 31-32 32-33

exact/norm bonds :
1-19 1-43 17-20 20-21 21-22 21-26 22-23 23-24 24-25 24-41 25-26 25-42
26-27 27-28 28-29 28-33 29-30 30-31 31-32 31-38 32-33 32-39 33-40
exact bonds :
1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15
15-16 16-17 17-18 23-34 30-36 34-35 36-37

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS
20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:Atom
29:Atom 30:Atom
31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS
39:CLASS 40:CLASS
41:CLASS 42:CLASS 43:CLASS

```

L17 STRUCTURE UPLOADED

```

=> f l17
SAMPLE SEARCH INITIATED 16:27:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       175 TO ITERATE

```

```

100.0% PROCESSED       175 ITERATIONS                           0 ANSWERS
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS: ONLINE   **COMPLETE**
                          BATCH    **COMPLETE**
PROJECTED ITERATIONS:     2707 TO    4293
PROJECTED ANSWERS:        0 TO      0

```

L18 0 SEA SSS SAM L17

```

=> s l17
SAMPLE SEARCH INITIATED 16:27:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       175 TO ITERATE

```

```

100.0% PROCESSED       175 ITERATIONS                           0 ANSWERS
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS: ONLINE   **COMPLETE**
                          BATCH    **COMPLETE**
PROJECTED ITERATIONS:     2707 TO    4293
PROJECTED ANSWERS:        0 TO      0

```

L19 0 SEA SSS SAM L17

```
=> d l17  
L17 HAS NO ANSWERS  
L17 STR
```

```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
```

```
Structure attributes must be viewed using STN Express query preparation.
```

```
=> s l17 sss full  
FULL SEARCH INITIATED 16:28:15 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 3311 TO ITERATE
```

```
100.0% PROCESSED 3311 ITERATIONS 46 ANSWERS  
SEARCH TIME: 00.00.01
```

```
L20 46 SEA SSS FUL L17
```

```
=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 172.55 379.36  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE 0.00 -20.28
```

```
FILE 'CAPLUS' ENTERED AT 16:28:19 ON 22 FEB 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 22 Feb 2007 VOL 146 ISS 9  
FILE LAST UPDATED: 21 Feb 2007 (20070221/ED)
```

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l20  
L21 19 L20
```

```
=> s l21 and (sepsis or septic)  
15030 SEPSIS  
13214 SEPTIC  
L22 1 L21 AND (SEPSIS OR SEPTIC)
```

```
=> d l22 ti abs bib
```

```
L22 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Treatment and prophylaxis of sepsis and septic shock  
with sophorolipids
```

AB A composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids is disclosed. The in vivo expts. demonstrated that sophorolipids have a protective effect against ongoing endotoxic shock. I.p. injection of sophorolipids 1.5 h after galactosamine-LPS treatment resulted in 53% lower mortality than that observed among pos. control mice.

AN 2004:905607 CAPLUS <<LOGINID::20070222>>

DN 141:355428

TI Treatment and prophylaxis of sepsis and septic shock with sophorolipids

IN Gross, Richard A.

PA USA

SO U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214795	A1	20041028	US 2004-807961	20040324
	CA 2557671	A1	20051013	CA 2005-2557671	20050324
	WO 2005094268	A2	20051013	WO 2005-US10060	20050324
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1729782	A2	20061213	EP 2005-730352	20050324
		R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU		
PRAI	US 2003-457070P	P	20030324		
	US 2004-807961	A	20040324		
	WO 2005-US10060	W	20050324		

=> s l21 and (shock)

143241 SHOCK

L23 1 L21 AND (SHOCK)

=> d l23 ti

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

TI Treatment and prophylaxis of sepsis and septic shock with sophorolipids

=> s l20/thu

19 L20

859285 THU/RL

L24 2 L20/THU

(L20 (L) THU/RL)

=> d l24 1-2 ti

L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Spermicidal and virucidal properties of various forms of sophorolipids produced by Candida bombicola

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Treatment and prophylaxis of sepsis and septic shock with sophorolipids

=> d 124 1 ti abs bib

L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Spermicidal and virucidal properties of various forms of sophorolipids produced by *Candida bombicola*
AB A method for producing sophorolipids having spermicidal and/or antiviral properties by synthesizing the sophorolipid by fermentation of *Candida bombicola*
in a fermentation media to form a natural mixture of lactonic sophorolipids compds. and non-lactonic sophorolipids compds. and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compds. for use as spermicidal and/or antiviral agents.

AN 2004:1038657 CAPLUS <<LOGINID::20070222>>

DN 142:22342

TI Spermicidal and virucidal properties of various forms of sophorolipids produced by *Candida bombicola*

IN Gross, Richard A.; Shah, Vishal; Doncel, Gustavo F.

PA USA

SO U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004242501	A1	20041202	US 2004-804778	20040319
	CA 2559808	A1	20050929	CA 2005-2559808	20050318
	WO 2005089522	A2	20050929	WO 2005-US9486	20050318
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1750726	A2	20070214	EP 2005-733074	20050318
		R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU		
PRAI	US 2003-456208P	P	20030320		
	US 2004-804778	A	20040319		
	WO 2005-US9486	W	20050318		

=> s 121 and (antibacterial)
92331 ANTIBACTERIAL

L25 2 L21 AND (ANTIBACTERIAL)

=> d 125 1-2 ti

L25 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Amino Acid Conjugated Sophorolipids: A New Family of Biologically Active Functionalized Glycolipids

L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Antimicrobial properties of various forms of sophorolipids

=> d 125 1-2 ti abs bib

L25 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Amino Acid Conjugated Sophorolipids: A New Family of Biologically Active Functionalized Glycolipids

AB Sophorolipids (SLs) are extra cellular glycolipids produced by *Candida bombicola* ATCC 22214 when grown in the presence of glucose and fatty acids. These compds. have a disaccharide head group connected to a long-chain hydroxyl-fatty acid by a glycosidic bond. To explore structure-activity of modified SLs, a new family of amino acid-SL derivs. was prepared. Synthesized analogs consist of amino acids linked by amide bonds formed between their α -amino moiety and the carboxyl group of ring-opened SL fatty acids. Their preparation involved the following: (i) hydrolysis of a natural SL mixture with aqueous alkali to give SL free acids, (ii) coupling of free acids to protected amino acids using dicarbodiimide, and (iii) removing amino acid carboxyl protecting groups. These conjugates were evaluated for their antibacterial, anti-HIV, and spermicidal activity. All tested analogs showed antibacterial activity against both gram pos. and gram neg. organisms. Leucine-conjugated SL was most efficient. For example, the min. inhibitory concns. (MIC) for *Moraxella* sp. and *E. coli* were 0.83 and 1.67 mg/mL, resp. Among the alkyl esters of amino acid conjugated SLs, the Et ester of leucine-SLs was most active. Against *Moraxella* sp., *S. sanguinis*, and *M. imperiale*, MIC values are 7.62×10^{-4} , 2.28×10^{-3} and 1.67 mg/mL, resp. All compds. displayed virus-inactivating activity with 50% effective concns. (EC50) below 200 μ g/mL. The EC50 of leucine-SL Et ester was 24.1 μ g/mL, showing that it is more potent than com. spermicide nonoxynol-9 (EC50 \approx 65 μ g/mL).

AN 2006:1136366 CAPLUS <<LOGINID::20070222>>

DN 146:41746

TI Amino Acid Conjugated Sophorolipids: A New Family of Biologically Active Functionalized Glycolipids

AU Azim, Abul; Shah, Vishal; Doncel, Gustavo F.; Peterson, Nicholas; Gao, Wei; Gross, Richard

CS NSF I/UCR Center for Biocatalysis and Bioprocessing of Macromolecules, Polytechnic University, Brooklyn, NY, 11201, USA

SO Bioconjugate Chemistry (2006), 17(6), 1523-1529
CODEN: BCCHE; ISSN: 1043-1802

PB American Chemical Society

DT Journal

LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Antimicrobial properties of various forms of sophorolipids

AB The preparation and use of 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-octadecenoate, lactonic and open ring 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-octadecenoate, Me 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-octadecenoate, Et 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-octadecenoate, hexyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-octadecenoate, Et 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-octadecenoate-6''-acetate and Et 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-cis-9-

octadecenoate-6',6'''-diacetate sophorolipids are antibacterial,
 antiviral and/or anti-spermicidal agents.
 AN 2004:430977 CAPLUS <<LOGINID::20070222>>
 DN 141:5877
 TI Antimicrobial properties of various forms of sophorolipids
 IN Gross, Richard A.; Shah, Vishal
 PA Polytechnic University, USA
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004044216	A1	20040527	WO 2003-US35871	20031106
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299557	A1	20040603	AU 2003-299557	20031106
	US 2005164955	A1	20050728	US 2004-20683	20041222
	WO 2006069175	A2	20060629	WO 2005-US46426	20051222
	WO 2006069175	A3	20060908		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2002-424271P	P	20021106		
	WO 2003-US35871	W	20031106		
	US 2004-20683	A2	20041222		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:43:39 ON 22 FEB 2007)

FILE 'CAPLUS' ENTERED AT 15:43:51 ON 22 FEB 2007

L1	64 S PROANTHOCYANIDIN AND (INFLAMM? OR ANTIINFLAMM?)
L2	1 S L1 AND DERMATITIS
L3	27 S L1 NOT PY>2002
L4	4 S L3 AND (DERMATITIS OR ATOPIA OR XEROSIS OR PSORIASIS OR SKIN
L5	145 S PROANTHOCYANIDIN AND (DERMATITIS OR ATOPIA OR XEROSIS OR PSOR
L6	58 S L5 NOT PY>2002
L7	5 S PROANTHOCYANIDIN AND (DERMATITIS OR ATOPIA OR XEROSIS OR PSOR

FILE 'REGISTRY' ENTERED AT 15:59:15 ON 22 FEB 2007

L8	1 S GLYCRRHETINIC ACID/CN
L9	0 S TEMESTEINE/CN

L10 1 S TELMESTEINE/CN

FILE 'CAPLUS' ENTERED AT 15:59:52 ON 22 FEB 2007

L11 1656 S L8
L12 48 S L11 AND (DERMATITIS OR PSORIASIS OR XEROSIS OR ATOPIA)
L13 23 S L12 NOT PY>2003
L14 2 S L10 AND (DERMATITIS OR PSORIASIS OR XEROSIS OR ATOPIA)
L15 1 S L10 AND (INFLAMM? OR ANTIINFLAMM?)
L16 3 S L10 AND (DERM? OR TOPICAL OR SKIN)

FILE 'REGISTRY' ENTERED AT 16:27:24 ON 22 FEB 2007

L17 STRUCTURE uploaded
L18 0 F L17
L19 0 S L17
L20 46 S L17 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:28:19 ON 22 FEB 2007

L21 19 S L20
L22 1 S L21 AND (SEPSIS OR SEPTIC)
L23 1 S L21 AND (SHOCK)
L24 2 S L20/THU
L25 2 S L21 AND (ANTIBACTERIAL)

=> log

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.89	405.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-23.40

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:31:40 ON 22 FEB 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:35:28 ON 22 FEB 2007
FILE 'CAPLUS' ENTERED AT 16:35:28 ON 22 FEB 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.89	405.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-23.40

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST	26.83	406.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-23.40

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPUS, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 16:36:32 ON 22 FEB 2007

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

```
=> s sophorolipid and shock
    1   FILE BIOSIS
<-----User Break----->
```

```
=> s sophorolipid and (shock or sepsis or bacteremia)
    2   FILE BIOSIS
    2   FILE CAPLUS
    1   FILE DDFU
    1   FILE DRUGU
    2   FILE EMBASE
```

33 FILES SEARCHED...

```
    1   FILE IFIPAT
    1   FILE MEDLINE
    1   FILE PASCAL
    3   FILE SCISEARCH
    2   FILE TOXCENTER
    5   FILE USPATFULL
    1   FILE WPIDS
    1   FILE WPINDEX
```

13 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L26 QUE SOPHOROLIPID AND (SHOCK OR SEPSIS OR BACTEREMIA)

=> file biosis embase medline scisearch uspatfull		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	407.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-23.40

FILE 'BIOSIS' ENTERED AT 16:37:59 ON 22 FEB 2007
 Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:37:59 ON 22 FEB 2007
 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:37:59 ON 22 FEB 2007

FILE 'SCISEARCH' ENTERED AT 16:37:59 ON 22 FEB 2007
 Copyright (c) 2007 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 16:37:59 ON 22 FEB 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s sophorolipid and (shock or sepsis or bacteremia)

L27

13 SOPHOROLIPID AND (SHOCK OR SEPSIS OR BACTEREMIA)

=> dup rem L27

PROCESSING COMPLETED FOR L27

L28 10 DUP REM L27 (3 DUPLICATES REMOVED)

=> d 128 1-10 ti

L28 ANSWER 1 OF 10 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

TI Sophorolipids in sepsis: Antiinflammatory or antibacterial?.

L28 ANSWER 2 OF 10 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 1

TI Sophorolipid treatment decreases inflammatory cytokine expression in an in vitro model of experimental sepsis.

L28 ANSWER 3 OF 10 MEDLINE on STN DUPLICATE 2

TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.

L28 ANSWER 4 OF 10 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.

L28 ANSWER 5 OF 10 USPATFULL on STN

TI Antifungal properties of various forms of sophorolipids

L28 ANSWER 6 OF 10 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 3

TI Sophorolipid treatment modulates leukocyte adhesion molecule profiles in intra-abdominal sepsis.

L28 ANSWER 7 OF 10 USPATFULL on STN

TI Spermicidal and virucidal properties of various forms of sophorolipids

L28 ANSWER 8 OF 10 USPATFULL on STN

TI Treatment and prophylaxis of sepsis and septic shock

L28 ANSWER 9 OF 10 USPATFULL on STN

TI Trehalose lipid tetraesters

L28 ANSWER 10 OF 10 USPATFULL on STN

TI Powdered compressed cosmetic material

=> d 128 1-10 ti abs bib

L28 ANSWER 1 OF 10 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

TI Sophorolipids in sepsis: Antiinflammatory or antibacterial?
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

AN 2006010951 EMBASE <>LOGINID::20070222>>

TI Sophorolipids in sepsis: Antiinflammatory or antibacterial?.

AU Napolitano L.M.

CS Dr. L.M. Napolitano, Department of Surgery, University of Michigan, School of Medicine, Ann Arbor, MI, United States

SO Critical Care Medicine, (2006) Vol. 34, No. 1, pp. 258-259. .

Refs: 14

ISSN: 0090-3493 CODEN: CCMDC7

CY United States

DT Journal; Editorial

FS 004 Microbiology

024 Anesthesiology
037 Drug Literature Index
LA English
ED Entered STN: 19 Jan 2006
Last Updated on STN: 19 Jan 2006

L28 ANSWER 2 OF 10 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 1

TI Sophorolipid treatment decreases inflammatory cytokine expression in an in vitro model of experimental sepsis.

AB Sophorolipids are a class of membrane-derived glycolipids that have wide ranging potential as treatment in clinical practice. Previous data from our laboratory show that in vivo sophorolipid therapy decreases sepsis related mortality in experimental models. In this study we investigated the effects of sophorolipid treatment on cytokine production in an in vitro model of experimental sepsis. LPS stimulated rat alveolar macrophage cells (NR8383) were cultured in the presence or absence of sophorolipids for 12, 24, 36; and 48 hr. RNA was harvested from each group and assayed for cytokine expression using multiplex PCR. Statistical analyses were performed comparing the LPS treated group (L) with the LPS + sophorolipid treated group (L+S). TNF- α , a proinflammatory cytokine known to play a pivotal role in septic shock was significantly decreased in the L+S group compared to the L group at 12-24 hr, but trended upward at 36-48hr. Pro-inflammatory cytokines IL-1 α and IL-1 β followed the same pattern. IL-1 receptor antagonist (RA), which provides a protective effect in experimental sepsis, also showed decreased expression in the L+S compared to L group at 12-24 hr and an upward trend at 36-48hr. Similar expression pattern was found with IL-10, which may affect Th1/Th2 type T cell responses. Sophorolipid treatment decreases expression of important pro-inflammatory cytokines in an in vitro cellular sepsis model and this immunomodulation may be responsible, in part, for sophorolipid mediated decreases in sepsis related mortality. Sophorolipid treatment may delay or prevent sepsis progression by allowing host response immune mechanisms to exert their protective effects.

AN 2006:344333 BIOSIS <>LOGINID::20070222>>
DN PREV200600343465

TI Sophorolipid treatment decreases inflammatory cytokine expression in an in vitro model of experimental sepsis.

AU Mueller, Cathy M. [Reprint Author]; Lin, Yin-yao; Viterbo, Domenico; Pierre, Joelle; Murray, Shirley A.; Shah, Vishat; Gross, Richard; Schulze, Robert; Zenilman, Michael E.; Bluth, Martin H.

CS Suny Downstate Med Ctr, Brooklyn, NY 11203 USA

SO FASEB Journal, (MAR 6 2006) Vol. 20, No. 4, Part 1, pp. A204.
Meeting Info.: Experimental Biology 2006 Meeting. San Francisco, CA, USA. April 01 -05, 2006. Amer Assoc Anatomists; Amer Physiol Soc; Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol; Amer Soc Nutr; Amer Soc Pharmacol & Expt Therapeut.
CODEN: FAJOEC. ISSN: 0892-6638.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English
ED Entered STN: 12 Jul 2006
Last Updated on STN: 12 Jul 2006

L28 ANSWER 3 OF 10 MEDLINE on STN
DUPLICATE 2

TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.

AB OBJECTIVE: Sophorolipids, a family of natural and easily chemoenzymatically modified microbial glycolipids, are promising modulators of the immune response. The potential of the therapeutic effect of sophorolipids was investigated in vivo in a rat model of sepsis and in vitro by analysis of nitric oxide and cytokine

production. DESIGN: Prospective, randomized animal study. SETTING: Experimental laboratory. SUBJECTS: Male Sprague-Dawley rats, 200-240 g. INTERVENTIONS: Intra-abdominal sepsis was induced *in vivo* in 166 rats via cecal ligation and puncture (CLP); 60 rats were used to characterize the model. The remaining rats were treated with sophorolipids or vehicle (dimethylsulfoxide [DMSO]/physiologic saline) by intravenous (iv) tail vein or intraperitoneal (IP) injection immediately post-CLP (25/group). Survival rates were compared at 36 hrs after surgery. *In vitro*, macrophages were cultured in lipopolysaccharide (LPS) +/- sophorolipid and assayed for nitric oxide (NO) production and gene expression profiles of inflammatory cytokines. In addition, splenic lymphocytes isolated from CLP rats +/- sophorolipid treatment (three per group) were analyzed for cytokine production by RNase protection assay. MEASUREMENTS AND MAIN RESULTS: CLP with 16-gauge needles optimized sepsis induction and resultant mortality. Sophorolipid treatment improved rat survival by 34% (iv) and 14% (IP) in comparison with vehicle controls ($p < .05$ for iv treatment). Sophorolipids decreased LPS-induced macrophage NO production by 28% ($p < .05$). mRNA expression of interleukin (IL)-1 β was downregulated by 42.5 +/- 4.7% ($p < .05$) and transforming growth factor (TGF)- β 1 was upregulated by 11.7 +/- 1.5% ($p < .05$) in splenocytes obtained 6 hrs postsophorolipid treatment. LPS-treated macrophages cultured 36 hrs with sophorolipids showed increases in mRNA expression of IL-1 α (51.7%), IL-1 β (31.3%), and IL-6 (66.8%) ($p < .05$). CONCLUSIONS: Administration of sophorolipids after induction of intra-abdominal sepsis significantly decreases mortality in this model. This may be mediated in part by decreased macrophage NO production and modulation of inflammatory responses.

AN 2005693126 MEDLINE <<LOGINID::20070222>>
DN PubMed ID: 16374148
TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.
AU Bluth Martin H; Kandil Emad; Mueller Catherine M; Shah Vishal; Lin Yin-Yao; Zhang Hong; Dresner Lisa; Lempert Leonid; Nowakowski Maja; Gross Richard; Schulze Robert; Zenilman Michael E
CS SUNY Downstate Medical Center, Department of Surgery, Brooklyn, NY 11203, USA.. martin.bluth@downstate.edu
SO Critical care medicine, (2006 Jan) Vol. 34, No. 1, pp. 188-95.
Journal code: 0355501. ISSN: 0090-3493.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200601
ED Entered STN: 30 Dec 2005
Last Updated on STN: 21 Jan 2006
Entered Medline: 20 Jan 2006

L28 ANSWER 4 OF 10 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.
AB Objective: Sophorolipids, a family of natural and easily chemoenzymatically modified microbial glycolipids, are promising modulators of the immune response. The potential of the therapeutic effect of sophorolipids was investigated *in vivo* in a rat model of sepsis and *in vitro* by analysis of nitric oxide and cytokine production. Design: Prospective, randomized animal study. Setting: Experimental laboratory. Subjects: Male Sprague-Dawley rats, 200-240 g. Interventions: Intra-abdominal sepsis was induced *in vivo* in 166 rats via cecal ligation and puncture (CLP); 60 rats were used to characterize the model. The remaining rats were treated with sophorolipids or vehicle (dimethylsulfoxide [DMSO]/physiologic saline) by intravenous (iv) tail vein or intraperitoneal (IP) injection immediately

post-CLP (25/group). Survival rates were compared at 36 hrs after surgery. In vitro, macrophages were cultured in lipopolysaccharide (LPS) + sophorolipid and assayed for nitric oxide (NO) production and gene expression profiles of inflammatory cytokines. In addition, splenic lymphocytes isolated from CLP rats + sophorolipid treatment (three per group) were analyzed for cytokine production by RNase protection assay. Measurements and Main Results: CLP with 16-gauge needles optimized sepsis induction and resultant mortality. Sophorolipid treatment improved rat survival by 34% (iv) and 14% (IP) in comparison with vehicle controls ($p < .05$ for iv treatment). Sophorolipids decreased LPS-induced macrophage NO production by 28% ($p < .05$). mRNA expression of interleukin (IL)-1 β was downregulated by 42.5 ± 4.7% ($p < .05$) and transforming growth factor (TGF)- β 1 was upregulated by 11.7 ± 1.5% ($p < .05$) in splenocytes obtained 6 hrs postsophorolipid treatment. LPS-treated macrophages cultured 36 hrs with sophorolipids showed increases in mRNA expression of IL-1 α (51.7%), IL-1 β (31.3%), and IL-6 (66.8%) ($p < .05$). Conclusions: Administration of sophorolipids after induction of intra-abdominal sepsis significantly decreases mortality in this model. This may be mediated in part by decreased macrophage NO production and modulation of inflammatory responses. Copyright © 2005 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins.

AN 2006010904 EMBASE <>LOGINID::20070222>>
TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.
AU Bluth M.H.; Kandil E.; Mueller C.M.; Shah V.; Lin Y.-Y.; Zhang H.; Dresner L.; Lempert L.; Nowakowski M.; Gross R.; Schulze R.; Zenilman M.E.
CS Dr. M.H. Bluth, Department of Surgery and Pathology, SUNY Downstate Medical Center, Box 40, 450 Clarkson Avenue, Brooklyn, NY 11203, United States. martin.bluth@downstate.edu
SO Critical Care Medicine, (2006) Vol. 34, No. 1, pp. E188.1-E188.8. .
Refs: 71
ISSN: 0090-3493 CODEN: CCMDC7
CY United States
DT Journal; Article
FS 004 Microbiology
030 Pharmacology
037 Drug Literature Index
048 Gastroenterology
LA English
SL English
ED Entered STN: 19 Jan 2006
Last Updated on STN: 19 Jan 2006

L28 ANSWER 5 OF 10 USPATFULL on STN
TI Antifungal properties of various forms of sophorolipids
AB The preparation and use of 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Lactonic and Open ring 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6"-acetate and Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6"-diacetate sophorolipids as antifungal agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:190039 USPATFULL <>LOGINID::20070222>>
TI Antifungal properties of various forms of sophorolipids
IN Gross, Richard A., Plainview, NY, UNITED STATES
Shah, Vishal, Plainsboro, NY, UNITED STATES
PI US 2005164955 A1 20050728

AI US 2004-20683 A1 20041222 (11)
RLI Continuation-in-part of Ser. No. WO 2003-US35871, filed on 6 Nov 2003,
PENDING
DT Utility
FS APPLICATION
LREP TECHNOPROP COLTON, L.L.C., P O BOX 567685, ATLANTA, GA, 311567685, US
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 6 OF 10 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 3

TI Sophorolipid treatment modulates leukocyte adhesion molecule
profiles in intra-abdominal sepsis.

AB Introduction: We have previously demonstrated that sophorolipids decrease
sepsis related mortality. In this study, we investigated changes
in cell surface expression profiles of helper/cytotoxic T cells (CD4,
CD8), and adhesion molecules including ICAM (CD54), L-selectin (CD62L) and
integrins (CD11a, CD11b/c) on blood leukocytes obtained from
sophorolipid treated septic rats, compared with untreated and sham
(laparotomy) controls. Materials and Methods: Intra-abdominal
sepsis was induced in rats via cecal ligation and puncture (CLP).
Sophorolipids or vehicle alone were injected IV at the end of the
operation. Blood leukocytes were harvested after 24 hrs and incubated
with conjugated antibodies. Leukocyte subsets and expression of cell
surface antigens were determined by flow cytometry. Results:
Sophorolipid treated rats showed a 67% increase in lymphocyte
CD11b/cexpression when compared with untreated controls ($p < 0.05$) and a
trend toward decreased lymphocyte CD54 and CD62L expression. Lymphocyte
CD11a expression was similar in both groups. CD4+ and CD8+ cells were
47-80% reduced in both CLP groups (+/- sophorolipid treatment)
when compared with sham group ($p < 0.05$). Conclusions: Sophorolipid
treatment after induction of intra-abdominal sepsis may improve
survival by modulation of leukocyte adhesion molecule expression. This
suggests that the integrin pathway is important in this promising new
therapy.

AN 2005:529855 BIOSIS <>LOGINID::20070222>>

DN PREV200510323370

TI Sophorolipid treatment modulates leukocyte adhesion molecule
profiles in intra-abdominal sepsis.

AU Bluth, Martin H. [Reprint Author]; Hardin, Rosemarie; Pierre, Joelle;
Chapman, Michael; Viterbo, Domenico; Lin, Yin Yao; Mueller, Cathy M.;
Chice, Seto; Schulze, Robert; Smith-Norowitz, Tamar A.; Nowakowski, Maja;
Kandil, Emad; Shah, Vishal; Gross, Richard A.; Zenilman, Michael E.

CS Suny Downstate Med Ctr, Brooklyn, NY 11203 USA

SO FASEB Journal, (MAR 4 2005) Vol. 19, No. 4, Suppl. S, Part 1, pp. A352.
Meeting Info.: Experimental Biology 2005 Meeting/35th International
Congress of Physiological Sciences. San Diego, CA, USA. March 31 -April
06, 2005. Amer Assoc Anatomists; Amer Assoc Immunologists; Amer Physiol
Soc; Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol; Amer Soc
Nutr Sci; Amer Soc Pharmacol & Expt Therapeut; Int Union Physiol Sci.
CODEN: FAJOEC. ISSN: 0892-6638.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 1 Dec 2005

Last Updated on STN: 1 Dec 2005

L28 ANSWER 7 OF 10 USPATFULL on STN

TI Spermicidal and virucidal properties of various forms of sophorolipids
AB A method for producing sophorolipids having spermicidal and/or antiviral
properties by synthesizing the sophorolipid by fermentation of

Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compounds for use as spermicidal and/or antiviral agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:307825 USPATFULL <<LOGINID::20070222>>
TI Spermicidal and virucidal properties of various forms of sophorolipids
IN Gross, Richard A., Plainview, NY, UNITED STATES
Shah, Vishal, Queens, NY, UNITED STATES
Doncel, Gustavo F., Norfolk, VA, UNITED STATES
PI US 2004242501 A1 20041202
AI US 2004-804778 A1 20040319 (10)
PRAI US 2003-456208P 20030320 (60)
DT Utility
FS APPLICATION
LREP TECHNOPROP COLTON, L.L.C., P O BOX 567685, ATLANTA, GA, 311567685
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 8 OF 10 USPATFULL on STN
TI Treatment and prophylaxis of sepsis and septic shock
AB A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:274293 USPATFULL <<LOGINID::20070222>>
TI Treatment and prophylaxis of sepsis and septic shock
IN Gross, Richard A., Plainview, NY, UNITED STATES
PI US 2004214795 A1 20041028
AI US 2004-807961 A1 20040324 (10)
PRAI US 2003-457070P 20030324 (60)
DT Utility
FS APPLICATION
LREP TECHNOPROP COLTON, L.L.C., P O BOX 567685, ATLANTA, GA, 311567685
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 9 OF 10 USPATFULL on STN
TI Trehalose lipid tetraesters
AB Anionic, surface-active trehalose lipids, in which different organic acids are bound to a trehalose molecule by an ester linkage, are prepared by aerobically cultivating trehalose-producing microorganisms, capable of assimilating hydrocarbons, under growth-limiting conditions, but without limiting the oxygen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 88:4250 USPATFULL <<LOGINID::20070222>>
TI Trehalose lipid tetraesters
IN Wagner, Fritz, Stockheim, Germany, Federal Republic of
Ristau, Egbert, Wolfsburg, Germany, Federal Republic of
Li, Zu-yi, Brunswick, Germany, Federal Republic of

Lang, Siegmund, Brunswick, Germany, Federal Republic of
Schulz, Walther, Staufenberg, Germany, Federal Republic of
Hofmann, Hans-Jurgen, Vechta, Germany, Federal Republic of
Sewe, Kai-Udo, Barnstorf, Germany, Federal Republic of
Lindorfer, Walter, Kassel, Germany, Federal Republic of
PA Wintershall AG, Kassel, Germany, Federal Republic of (non-U.S.
corporation)
PI US 4720456 19880119
AI US 1986-898838 19860820 (6)
RLI Continuation of Ser. No. US 1984-609120, filed on 11 May 1984, now
abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Goldberg, Jerome D.; Assistant Examiner: Lipovsky,
Joseph A.
LREP Meller, Michael N.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 10 OF 10 USPATFULL on STN
TI Powdered compressed cosmetic material
AB A powdered compressed cosmetic material comprising a
hydroxypropyl-etherified glycolipid ester represented by the general
formula; ##STR1## wherein R.sup.1 represents a methyl group or a
hydrogen atom, R.sup.2 represents a saturated or unsaturated hydrocarbon
group having carbon atoms of 11 to 15 when R.sup.1 is a methyl group, or
R.sup.2 represents a saturated or unsaturated hydrocarbon group having
carbon atoms of 12 to 16 when R.sup.1 is a hydrogen atom, A represents
the group ##STR2## R.sup.3 represents a saturated or unsaturated
hydrocarbon group having carbon atoms of 1 to 20 or -(A).sub.h H, and
a, b, c, d, e, f, g and h are integers, whose sum ranges from 1 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 81:68239 USPATFULL <<LOGINID::20070222>>
TI Powdered compressed cosmetic material
IN Kawano, Junichi, Sakura, Japan
Utsugi, Toshiaki, Tokyo, Japan
Inoue, Shigeo, Ichikai, Japan
Hayashi, deceased, Shizuo, late of Sugito, Japan by Horuko Hayashi
PA Kao Soap Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 4305931 19811215
AI US 1979-78156 19790924 (6)
PRAI JP 1978-120273 19780929
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Oblon, Fisher, Spivak, McClelland & Maier
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.